Federal Project Grant Award Summary

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $201,744 to The Regents of the University of California, San Francisco, with an award date of April 15, 2026, and completion date of March 31, 2031, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award funds research to elucidate the transcriptional mechanisms governing dysregulated Type 17 mucosal inflammation mediated by group 3 innate lymphoid cells (ILC3s), with applications to chronic inflammatory diseases including inflammatory bowel disease, psoriatic arthritis, and lupus. The research will employ a physiologically relevant A20 knock-in mouse model and integrate in vivo immune profiling, transcriptomic analysis, and chromatin mapping techniques.

The project delivers fundamental scientific knowledge through two primary research aims: first, determining how ILC3 abundance influences tissue homeostasis and inflammation by investigating their effects on T cell populations and inflammatory programs, and second, defining the role of ZBTB transcription factors in ILC3 maintenance and Type 17 inflammation regulation. The anticipated products include identification of epigenetic and immune regulatory mechanisms underlying pathogenic inflammation, discovery of molecular pathways governing ILC3 dysregulation, and potential therapeutic targets for restoring immune homeostasis in chronic inflammatory diseases.